Lupin shares faced notable selling pressure down 1.84 percent to touch an intraday low of ₹2,144.70. The downward price action was driven by a major global brokerage firm downgrading the pharma counter to a sell rating while cutting its targeted investment price framework substantially to ₹2,050 citing structural valuation hurdles.